UK Biobank

Genes and pathways related to mesenchymal biology, connective tissue, and conditions like obesity came to the forefront when researchers analyzed the new susceptibility loci.

To explore the genetic basis of clonal hematopoiesis and its consequences, researchers analyzed genotyping data for more than 151,000 UK Biobank participants.

The project will focus on metabolic biomarkers that previous research has linked to heart disease, type 2 diabetes, and other common chronic diseases.

Regeneron Pharmaceuticals and its collaborators plan to sequence the exomes all of the UK Biobank participants by then end of 2019.

Still Evolving

A new paper in PNAS finds that people are still evolving, but with increased pressure on weight and decreased pressure on intelligence.

Regeneron Pharmaceuticals

Since 2015, the Regeneron Genetics Center has sequenced 250,000 exomes from phenotyped individuals, identifying "human knockouts" and other large-effect mutations.

More than 200 bone mineral density-linked loci turned up using data for over 140,000 individuals, including 153 new loci.

A life sciences industrial strategy out this week provided long-term guidance for supporting and enhancing growth in the sector in the UK.

The release has been accompanied by acute interest from the genomics community, which views the resource as a "game changer" for anyone working in human genetics.

The four-year project, which ended in 2010, collected DNA samples and lifestyle information from half a million people from the UK.

Pages

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.